Apellis Pharmaceuticals (APLS) Stock Forecast, Price Target & Predictions
APLS Stock Forecast
Apellis Pharmaceuticals stock forecast is as follows: an average price target of $75.81 (represents a 101.52% upside from APLS’s last price of $37.62) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
APLS Price Target
The average price target for Apellis Pharmaceuticals (APLS) is $75.81 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $113.00 to $48.00. This represents a potential 101.52% upside from APLS's last price of $37.62.
APLS Analyst Ratings
According to 15 Wall Street analysts, Apellis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for APLS stock is 1 'Strong Buy' (6.67%), 11 'Buy' (73.33%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Apellis Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Colleen Kusy | Robert W. Baird | $96.00 | $37.66 | 154.91% | 155.18% |
| Aug 08, 2024 | Akash Tewari | Jefferies | $82.00 | $37.66 | 117.74% | 117.97% |
| Aug 02, 2024 | Douglas Tsao | H.C. Wainwright | $83.00 | $36.00 | 130.56% | 120.63% |
| Jul 26, 2024 | Colleen Kusy | Robert W. Baird | $86.00 | $38.88 | 121.19% | 128.60% |
| Jul 01, 2024 | Graig Suvannavejh | Mizuho Securities | $49.00 | $38.36 | 27.74% | 30.25% |
| May 23, 2024 | Derek Archila | Wells Fargo | $48.00 | $43.60 | 10.09% | 27.59% |
| Feb 05, 2024 | Akash Tewari | Jefferies | $80.00 | $68.16 | 17.37% | 112.65% |
| Jan 02, 2023 | Derek Archila | Wells Fargo | $58.00 | $51.71 | 12.16% | 54.17% |
| Nov 15, 2022 | - | J.P. Morgan | $79.00 | $46.61 | 69.49% | 109.99% |
| Sep 12, 2022 | - | Wedbush | $67.00 | $67.07 | -0.10% | 78.10% |
The latest Apellis Pharmaceuticals stock forecast, released on Aug 09, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $96.00, which represents a 154.91% increase from the stock price at the time of the forecast ($37.66), and a 155.18% increase from APLS last price ($37.62).
Apellis Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 5 | 7 |
| Avg Price Target | - | $79.20 | $74.86 |
| Last Closing Price | $37.62 | $37.62 | $37.62 |
| Upside/Downside | -100.00% | 110.53% | 98.99% |
In the current month, the average price target of Apellis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Apellis Pharmaceuticals's last price of $37.62. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Wedbush | Neutral | Neutral | Hold |
| Aug 08, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Aug 02, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 02, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 31, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 22, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 28, 2024 | Wedbush | Underperform | Underperform | Hold |
| Jun 28, 2024 | Wells Fargo | Buy | Buy | Hold |
| May 31, 2024 | Piper Sandler | - | Neutral | Initialise |
Apellis Pharmaceuticals's last stock rating was published by Wedbush on Aug 09, 2024. The company gave APLS a "Neutral" rating, the same as its previous rate.
Apellis Pharmaceuticals Financial Forecast
Apellis Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $99.18M | $89.64M | $44.85M | $22.66M | $22.06M | - | $14.38M | $60.29M | $5.65M | $623.00K | - | $250.00M | $646.00K |
| Avg Forecast | $265.22M | $242.41M | $237.58M | $223.48M | $216.55M | $201.66M | $190.89M | $163.27M | $143.34M | $99.05M | $70.24M | $26.11M | $24.41M | $21.59M | $16.95M | $12.57M | $8.79M | $7.23M | $500.10K | $2.50M | $109.83M | $570.21K |
| High Forecast | $286.96M | $262.29M | $257.06M | $241.81M | $234.30M | $211.91M | $206.54M | $176.65M | $149.09M | $107.18M | $76.00M | $28.25M | $26.41M | $23.36M | $16.95M | $14.86M | $10.38M | $8.54M | $591.09K | $2.95M | $129.81M | $684.25K |
| Low Forecast | $248.27M | $226.92M | $222.40M | $209.20M | $202.71M | $189.65M | $178.69M | $152.83M | $139.14M | $92.72M | $65.75M | $24.44M | $22.85M | $20.21M | $16.95M | $10.83M | $7.57M | $6.23M | $430.86K | $2.15M | $94.62M | $456.17K |
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.28% | 1.72% | 0.93% | 1.02% | - | 1.14% | 6.86% | 0.78% | 1.25% | - | 2.28% | 1.13% |
Apellis Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 12 analysts is $143.34M, with a low forecast of $139.14M, and a high forecast of $149.09M. APLS's average Quarter revenue forecast represents a 44.52% increase compared to the company's last Quarter revenue of $99.18M (Sep 23).
Apellis Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-148.30M | $-125.77M | $-169.57M | $-159.30M | $-149.67M | - | $-128.83M | $-144.19M | $-193.01M | $-214.98M | $-179.09M | $87.93M | $-125.89M |
| Avg Forecast | $-150.41M | $-137.48M | $-134.73M | $-126.74M | $-122.81M | $-114.37M | $-108.26M | $-144.07M | $-81.29M | $-56.17M | $-39.84M | $-130.98M | $-13.84M | $-148.01M | $-9.61M | $-119.07M | $-137.63M | $-134.56M | $-94.59M | $-76.54M | $-62.28M | $-109.15M |
| High Forecast | $-140.79M | $-128.69M | $-126.12M | $-118.64M | $-114.96M | $-107.55M | $-101.34M | $-115.26M | $-78.91M | $-52.58M | $-37.29M | $-104.78M | $-12.96M | $-118.41M | $-9.61M | $-95.26M | $-110.11M | $-107.65M | $-75.67M | $-61.23M | $-53.66M | $-87.32M |
| Low Forecast | $-162.74M | $-148.75M | $-145.78M | $-137.13M | $-132.87M | $-120.18M | $-117.13M | $-172.89M | $-84.55M | $-60.78M | $-43.10M | $-157.17M | $-14.98M | $-177.62M | $-9.61M | $-142.88M | $-165.16M | $-161.47M | $-113.51M | $-91.84M | $-73.62M | $-130.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.64% | 3.16% | 1.29% | 11.51% | 1.01% | - | 1.08% | 1.05% | 1.43% | 2.27% | 2.34% | -1.41% | 1.15% |
10 analysts predict APLS's average Quarter EBITDA for Mar 21 to be $-76.54M, with a high of $-61.23M and a low of $-91.84M. This is -187.04% lower than Apellis Pharmaceuticals's previous annual EBITDA (Dec 20) of $87.93M.
Apellis Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | $-140.24M | $-122.04M | $-177.78M | $-165.99M | $-191.27M | - | $-138.94M | $-147.93M | $-195.57M | $-219.19M | $-183.66M | $78.27M | $-135.70M |
| Avg Forecast | $15.76M | $-13.13M | $-16.54M | $-26.12M | $-24.21M | $-36.49M | $-37.94M | $-155.38M | $-90.54M | $-123.10M | $-168.48M | $-141.25M | $-188.40M | $-149.98M | $-173.90M | $-128.41M | $-141.21M | $-136.34M | $-96.44M | $-114.73M | $228.22M | $-117.66M |
| High Forecast | $17.44M | $-12.04M | $-15.17M | $-23.95M | $-22.19M | $-23.91M | $-34.79M | $-124.30M | $-6.86M | $-112.87M | $-154.48M | $-113.00M | $-172.75M | $-119.98M | $-173.90M | $-102.73M | $-112.97M | $-109.07M | $-77.16M | $-91.78M | $273.86M | $-94.13M |
| Low Forecast | $14.45M | $-14.53M | $-18.31M | $-28.91M | $-26.79M | $-54.11M | $-41.99M | $-186.45M | $-139.93M | $-136.22M | $-186.43M | $-169.50M | $-208.48M | $-179.97M | $-173.90M | $-154.09M | $-169.45M | $-163.61M | $-115.73M | $-137.68M | $182.58M | $-141.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 0.72% | 1.26% | 0.88% | 1.28% | - | 1.08% | 1.05% | 1.43% | 2.27% | 1.60% | 0.34% | 1.15% |
Apellis Pharmaceuticals's average Quarter net income forecast for Mar 21 is $-114.73M, with a range of $-137.68M to $-91.78M. APLS's average Quarter net income forecast represents a -246.59% decrease compared to the company's last Quarter net income of $78.27M (Dec 20).
Apellis Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | $145.65M | $111.37M | $102.09M | $84.37M | $78.41M | - | $51.19M | $41.46M | $45.76M | $48.97M | $40.58M | $44.49M | $36.99M |
| Avg Forecast | $485.09M | $443.39M | $434.54M | $408.76M | $396.07M | $368.85M | $349.15M | $57.24M | $262.18M | $181.17M | $128.48M | $47.75M | $44.65M | $39.49M | $30.99M | $23.00M | $16.07M | $13.22M | $914.70K | $4.57M | $200.88M | $1.04M |
| High Forecast | $524.87M | $479.74M | $470.17M | $442.27M | $428.55M | $387.59M | $377.77M | $68.69M | $272.69M | $196.03M | $139.01M | $51.67M | $48.31M | $42.73M | $30.99M | $27.18M | $18.99M | $15.62M | $1.08M | $5.40M | $237.43M | $1.25M |
| Low Forecast | $454.09M | $415.05M | $406.77M | $382.63M | $370.76M | $346.88M | $326.83M | $45.80M | $254.50M | $169.59M | $120.26M | $44.70M | $41.80M | $36.97M | $30.99M | $19.81M | $13.85M | $11.39M | $788.06K | $3.94M | $173.07M | $834.35K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.80% | 0.87% | 2.14% | 1.89% | 1.99% | - | 2.23% | 2.58% | 3.46% | 53.53% | 8.87% | 0.22% | 35.47% |
Apellis Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $262.18M, based on 12 Wall Street analysts, with a range of $254.50M to $272.69M. The forecast indicates a 80.01% rise compared to APLS last annual SG&A of $145.65M (Sep 23).
Apellis Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.17 | $-1.02 | $-1.56 | $-1.52 | $-1.75 | - | $-1.42 | $-1.73 | $-2.28 | $-2.72 | $-2.32 | $0.99 | $-1.79 |
| Avg Forecast | $0.13 | $-0.11 | $-0.13 | $-0.21 | $-0.20 | $-0.29 | $-0.31 | $-0.48 | $-0.73 | $-0.99 | $-1.36 | $-1.48 | $-1.52 | $-1.46 | $-1.41 | $-1.33 | $-1.54 | $-1.69 | $-1.72 | $-1.64 | $-0.67 | $-1.57 |
| High Forecast | $0.14 | $-0.10 | $-0.12 | $-0.19 | $-0.18 | $-0.19 | $-0.28 | $-0.44 | $-0.06 | $-0.91 | $-1.25 | $-1.36 | $-1.39 | $-1.34 | $-1.41 | $-1.09 | $-1.26 | $-1.39 | $-1.41 | $-1.34 | $-0.55 | $-1.29 |
| Low Forecast | $0.12 | $-0.12 | $-0.15 | $-0.23 | $-0.22 | $-0.44 | $-0.34 | $-0.53 | $-1.13 | $-1.10 | $-1.50 | $-1.64 | $-1.68 | $-1.62 | $-1.41 | $-1.65 | $-1.90 | $-2.09 | $-2.12 | $-2.02 | $-0.82 | $-1.94 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.18% | 0.75% | 1.06% | 1.00% | 1.20% | - | 1.06% | 1.12% | 1.35% | 1.58% | 1.42% | -1.49% | 1.14% |
According to 10 Wall Street analysts, Apellis Pharmaceuticals's projected average Quarter EPS for Mar 21 is $-1.64, with a low estimate of $-2.02 and a high estimate of $-1.34. This represents a -265.31% decrease compared to APLS previous annual EPS of $0.99 (Dec 20).
Apellis Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| IMVT | Immunovant | $29.67 | $42.83 | 44.35% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
APLS Forecast FAQ
Is Apellis Pharmaceuticals a good buy?
Yes, according to 15 Wall Street analysts, Apellis Pharmaceuticals (APLS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 11 'Buy' recommendations, accounting for 80.00% of APLS's total ratings.
What is APLS's price target?
Apellis Pharmaceuticals (APLS) average price target is $75.81 with a range of $48 to $113, implying a 101.52% from its last price of $37.62. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Apellis Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for APLS stock, the company can go up by 101.52% (from the last price of $37.62 to the average price target of $75.81), up by 200.37% based on the highest stock price target, and up by 27.59% based on the lowest stock price target.
Can Apellis Pharmaceuticals stock reach $60?
APLS's average twelve months analyst stock price target of $75.81 supports the claim that Apellis Pharmaceuticals can reach $60 in the near future.
What are Apellis Pharmaceuticals's analysts' financial forecasts?
Apellis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $772.37M (high $829.41M, low $723.88M), average EBITDA is $-490M (high $-439M, low $-543M), average net income is $-254M (high $-205M, low $-309M), average SG&A $1.17B (high $1.26B, low $1.09B), and average EPS is $-1.274 (high $-1.091, low $-1.52). APLS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $968.7M (high $1.05B, low $906.78M), average EBITDA is $-549M (high $-514M, low $-594M), average net income is $-40.042M (high $-33.725M, low $-47.299M), average SG&A $1.77B (high $1.92B, low $1.66B), and average EPS is $-0.323 (high $-0.272, low $-0.382).
Did the APLS's actual financial results beat the analysts' financial forecasts?
Based on Apellis Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $366.28M, beating the average analysts forecast of $338.75M by 8.13%. Apple's EBITDA was $-547M, beating the average prediction of $-308M by 77.58%. The company's net income was $-529M, beating the average estimation of $-523M by 1.01%. Apple's SG&A was $500.82M, missing the average forecast of $619.58M by -19.17%. Lastly, the company's EPS was $-4.45, missing the average prediction of $-4.562 by -2.46%. In terms of the last quarterly report (Sep 2023), Apellis Pharmaceuticals's revenue was $99.18M, beating the average analysts' forecast of $99.05M by 0.13%. The company's EBITDA was $-148M, beating the average prediction of $-56.175M by 163.99%. Apellis Pharmaceuticals's net income was $-140M, beating the average estimation of $-123M by 13.92%. The company's SG&A was $145.65M, missing the average forecast of $181.17M by -19.61%. Lastly, the company's EPS was $-1.17, beating the average prediction of $-0.993 by 17.77%